HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Canadian cosmetic "cost recovery" program

This article was originally published in The Rose Sheet

Executive Summary

Canadian cosmetic "cost recovery" program: Beginning in 1997, Canada's Health Protection Branch plans to levy a Cosmetics Notification fee of $140 (Canadian). The cosmetics proposal is expected to be published in Canada Gazette Part I in six to eight months, according to Canadian health officials. Once implemented, the cosmetics fees are projected to generate approximately $300,000 (Canadian) of a forecasted $39.8 mil. (Canadian) in fees generated from the Canadian drug "cost recovery" program in 1997. Beginning in January, Canada began collecting fees for the "authority to sell drugs" ("The Rose Sheet" Nov. 14, In Brief). Other upcoming drug user fees include Submission fees and Establishment License fees, according to a recent Health Canada discussion document on the issue...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel